SANA · Sana Biotechnology, Inc. · Debt
$2.41
+0.11 (+4.77%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$688.53M
Shares
299.36M
Volume · Oct 20
3.48M
Avg daily vol (3M)
3.2M
Debt Profile
Completed filing coverage through Jun 1, 2022Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 73,739,000 | 10-Q filed 2026-08-10 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
14 filings
14 filers
Visit website
Investor relations